Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on identifying and advancing innovative therapeutic opportunities. Company updates have covered financial results, capital resources, restructuring and impairment charges, strategic development efforts, licensing activity, and subsidiary actions through Axion Bio.
Recent announcements also document the completed discontinuation of clinical development of AXN-2510 and the termination of related license and collaboration rights, after earlier updates on the PD-L1xVEGF bispecific antibody program, FDA IND clearance, non-small cell lung cancer data presented by ImmuneOnco, and solid-tumor development activity.
Instil Bio, Inc. reported its Q2 2022 results, highlighting continued enrollment in its DELTA-1 clinical trial of ITIL-168 for advanced melanoma, with top-line data expected in early 2024. The company aims to extend its cash runway into 2025, supported by a potential sale-leaseback of its Tarzana, CA manufacturing site. Key initiatives include the initiation of Phase 1 trials for ITIL-306 and ITIL-168 in combination with pembrolizumab for various cancers. However, Instil reported a net loss of $58.99 million, with total cash and equivalents down to $354.6 million from $454.1 million year-over-year.
Instil Bio has received FDA IND clearance for its first genetically-engineered CoStAR-TIL therapy, ITIL-306, targeting non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and ovarian cancer. The Phase 1 clinical study will enroll its first patient soon, utilizing a novel regimen that eliminates post-infusion IL-2. Data to be presented at the 2022 ASCO Annual Meeting demonstrates CoStAR T cells' enhanced expansion and tumor control without the need for high-dose IL-2. This innovation aims to improve the safety and efficacy of TIL treatments.
Instil Bio (Nasdaq: TIL) announced promising results from genomic analyses of tumor-infiltrating lymphocyte (TIL) therapies for metastatic melanoma. An objective response rate (ORR) of 67% was observed in 14 out of 21 patients. Key findings correlate tumor response with TIL clonal expansion and specific T cell populations. The results, showcasing the analytical advances in TIL therapy, will be presented at the ASGCT Annual Meeting on May 18, 2022. The research aims to enhance TIL efficacy, providing insights into anti-cancer therapies.
Instil Bio (Nasdaq: TIL) reported its Q1 2022 financial results, highlighting a cash position of $61.5 million and marketable securities of $318 million. The company is focused on advancing its tumor infiltrating lymphocyte (TIL) therapies, with ongoing enrollment in the DELTA-1 trial targeting advanced melanoma, aiming for top-line data in 2023. Additionally, a Phase 1 study of ITIL-306 is set to start in Q2 2022. The cash runway is projected to extend into 2024, backed by significant preclinical data presentations scheduled for ASCO 2022.
Instil Bio initiated the DELTA-1 Phase 2 trial of ITIL-168 for advanced melanoma, receiving orphan drug and fast-track designations from the FDA. The company expanded its manufacturing in the UK and the California facility is expected to commence operations in H1 2022. Financially, as of December 31, 2021, Instil had $454.1 million in cash and equivalents. Their R&D expenses rose to $107.3 million for the year, reflecting a substantial increase from 2020. 2021 culminated in a net loss of $156.8 million, with significant operational developments expected in 2022.
Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical firm, will participate in the Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The panel discussion will focus on their tumor infiltrating lymphocyte (TIL) therapies aimed at treating patients with cancer. Interested parties can access a live webcast at this link, with an archived replay available for 90 days post-event. For more details, visit www.instilbio.com.
Instil Bio (NASDAQ: TIL) provided a corporate update and financial results for Q3 2021. Key highlights include the initiation of a Phase 2 trial (DELTA-1) for ITIL-168 in metastatic melanoma after receiving FDA IND clearance and Fast Track Designation. The company reported $20.4 million in cash and cash equivalents with $495 million in marketable securities as of September 30, 2021, enabling operations through 2023. Research and development expenses surged to $29.1 million for Q3 2021, compared to $4.9 million in 2020, reflecting ramped-up clinical efforts.
Instil Bio, Inc. (Nasdaq: TIL) announced the presentation of pre-clinical data for its CoStimulatory Antigen Receptor (CoStAR) platform at the SITC 2021. Key findings indicate that CoStAR significantly enhances the effector function of T cells when combined with tumor-reactive signals. Notably, the anti-FOLR1 CoStAR construct demonstrated over 40% transduction efficiency in primary ovarian cancer TILs. The company looks forward to initiating a Phase 1 study of ITIL-306 in early 2022, with the potential to reduce toxicity associated with high-dose IL-2.
Instil Bio, Inc. (Nasdaq: TIL) announced its participation in two investor conferences in November 2021. The Cowen 5th Annual IO Next Summit is scheduled for November 15, 2021, from 4:45 PM to 5:05 PM ET, with a live session link available. The Jefferies Global Healthcare Conference will be held on November 18, 2021, at 3:00 AM ET, also offering a live session link. An archived replay of both events will be accessible on the company's website for 90 days post-presentation. Instil is dedicated to developing TIL therapies targeting various cancers.
Instil Bio, Inc. (NASDAQ: TIL) presented a subset analysis of treatment outcomes for its TIL therapy at the ESMO Congress 2021. The analysis focused on 12 patients with checkpoint inhibitor-refractory advanced cutaneous melanoma. Among them, 58% achieved an objective response, with a median overall survival of 21.3 months, indicating the potential effectiveness of TIL therapy in difficult cases. The therapy demonstrated manageable side effects, primarily from the pre-treatment regimen. Instil aims to further explore TIL therapy in its upcoming Phase 2 DELTA-1 clinical trial.